Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp echanical circulatory support with a left ventricular assist device (LVAD) has become a well-established procedure for patients with end-stage heart failure. Patient selection and timing of implantation, however, remain critical issues. Although several studies have identified pre-implantation risk factors in regard to mortality, 1,2 most are limited by the fact that few of the reported patients were supported by an LVAD for a prolonged period. Because prolonged LVAD support has become prevalent not only as a bridge to transplantation but also for destination therapy, it is important to find preoperative risk factors for patients supported by an LVAD for a prolonged period. Preoperative cardiogenic shock is recognized as one of the significant risk factors for mortality after LVAD implantation, 2,3 and percutaneous cardiopulmonary support (PCPS), has been utilized for patients in cardiogenic shock to improve and stabilize the preoperative condition of LVAD candidates. 4,5 Although those studies demonstrated that PCPS can effectively act as a bridge to LVAD therapy for patients in cardiogenic shock, the duration of LVAD support in previous studies was relatively short, and the impact of preoperative PCPS on long-term LVAD support is not known. In Japan, because of a severe donor shortage, the average LVAD support period before heart transplantation is >2 years, 6 which provides a unique opportunity to observe LVAD patients for prolonged periods. In the present study we retrospectively reviewed 103 consecutive patients to clarify the impact of preoperative PCPS on long-term survival following implantation of an LVAD.
PCPS and LVAD Implantation 1999 and July 2010. All patients had been hospitalized at least once for New York Heart Association class IV heart failure and were receiving maximized medical regimens, including angiotensin-converting enzyme inhibitors, beta-blockers, and diuretics. Histological diagnosis was made based on preoperative biopsy findings, while the etiology of cardiomyopathy included dilated cardiomyopathy (n=73), dilated phase of hypertrophic cardiomyopathy (n=12), and secondary cardiomyopathy (myopathy, n=7; ischemia, n=6; sarcoidosis, n=3; drug, n=2). Prior to LVAD implantation, all patients were receiving i.v. inotropes. Furthermore 42 (41%) were supported by IABP alone, and 25 (24%) by PCPS, which consisted of a membrane oxygenator and centrifugal pump (Capiox, Terumo, Tokyo, Japan). Of 25 patients who were initially supported by PCPS before LVAD implantation, 12 required PCPS in order to improve multi-organ failure due to acute deterioration of heart failure; 6 required PCPS because of sudden hemodynamic collapse due to ventricular arrhythmia or cardiac arrest; 5 required PCPS because of acute hemodynamic collapse due to sepsis; 1 required PCPS during high-risk percutaneous coronary intervention for acute myocardial infarction and could not be weaned from it; and 1 could not be weaned from PCPS after high-risk coronary artery bypass grafting (CABG) with a mitral annuloplasty. Baseline characteristics are presented in Table 1 . As indicators of preoperative multi-organ failure, serum creatinine was >2.0 mg/dl in 16 patients (16%), and total bilirubin was >2.0 mg/dl in 45 patients (44%). Fourteen patients (14%) had a history of previous cardiac surgery including restrictive mitral annuloplasty (n=4), partial left ventriculectomy with mitral surgery (n=3), mitral valve replacement (n=2), surgical ventricular reconstruction with CABG (n=2), CABG (n=2), and LVAD placement (n=1). Preoperative left ventricular (LV) and atrial dimension and function, and cardiac output were evaluated on echocardiography ( Table 1) . The institutional ethics committee of National Cerebral and Cardiovascular Center approved this study and written informed consent for the procedure was obtained from all patients before surgery.
Surgical Technique
All surgical procedures were performed through a median sternotomy under a cardiopulmonary bypass (CPB). The outflow cannula was anastomosed to the ascending aorta, and inflow to the LV apex, without arresting the heart, to minimize ischemic insult to the right ventricle. The LVAD was then placed between the inflow and outflow cannulae. Ninety-one paracorporeal devices (Toyobo-VAS: Nipro) and 12 In addition, 78 concomitant procedures were performed and tepid blood cardioplegia was given in antegrade and retrograde fashion to obtain cardioplegic arrest in 9 cases.
Postoperative Management
During the immediate postoperative period pulmonary artery pressure and cardiac output were monitored, while cardiac output was maximized by optimizing the volume status and dosage of inotropes and phosphodiesterase inhibitor (PDEi). While the patient was intubated, nitric oxide was given in order to reduce pulmonary vascular resistance, and nitric oxide inhalation was switched to i.v. (Milrinone) and/or oral PDEi (Sildenafil) after extubation. After removing the pulmonary artery catheter, cardiac output was estimated, and volume status and right ventricular function were evaluated on transthoracic echocardiography. Echocardiographic measurement included LV end-diastolic and end-systolic diameters, left atrial diameter, LV ejection fraction and other routine variables, and cardiac output was measured at the right ventricular outflow tract. Anticoagulation was started using i.v. low-molecularweight heparin within 24 h after surgery, then switched to coumadin to maintain an international normalized ratio between 3 and 4 for patients with a Toyobo-VAS, or between 2 and 3 for patients with implantable devices (except for the HeartMate VE: only aspirin was given to these patients). After patients were discharged from the intensive care unit (ICU), ambulation was encouraged and cardiac rehabilitation was commenced. Those with an implantable device were discharged to home, after being trained to care for themselves and their device.
Statistical Analysis
Preoperative and postoperative variables were investigated by reviewing clinical records. Continuous variables are expressed as mean ± SD and were compared using a Mann-Whitney Data given as mean ± SD or n (%). CRT, cardiac resynchronization therapy.
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U-test for unpaired data and a Wilcoxon signed rank test for paired data. Categorical variables were compared using Fisher's exact test. Predictors of death were analyzed using a Cox proportional hazards model. Actuarial survival was analyzed using the Kaplan-Meier method, and survival curves were compared using a log-rank test. Data were analyzed using StatView 5.0 (SAS Institute, Cary, NC, USA) and P<0.05 was considered to be statistically significant.
Results

Early Results
We performed 78 concomitant procedures at the time of LVAD implantation and the mean CPB time was 161±54 min. Cardioplegic arrest was avoided as much as possible to reduce ischemic insult to the right ventricle. Cardioplegic arrest was applied in 9 patients and aortic cross-clamp time was 53±30 min ( Table 2) . Thirty-seven patients (36%) were weaned from CPB with nitric oxide inhalation and 2 patients who had PCPS preoperatively required mechanical right ventricular support for weaning from CPB. With regard to those 2 patients, right ventricular function was recovered and mechanical right ventricular support was removed at 8 days after LVAD implantation in 1 patient, while long-term right ventricular support with a Toyobo-VAS was required in the other. In addition, 23 patients (22%) required re-exploration for mediastinal bleeding and 18 (17%) required a tracheostomy for prolonged respiratory support. Although 16 patients (16%) required continuous hemofiltration to treat postoperative acute renal failure, none needed chronic hemodialysis and there were no early mortalities within 30 days after LVAD implantation among the 103 LVAD patients.
Late Results
The patients had an LVAD for 560±391 days (range, 17-1,567 days). During LVAD support 48 patients had 113 cerebrovascular events including hemorrhage, infarction, and transient ischemic attacks, and the rate of cerebrovascular events was calculated to be 0.72 events per patient per year. Bloodstream infections occurred in 57 patients (55%), from whom the LVAD was removed in 2 and exchanged in 1 because of an intractable bloodstream infection. When right ventricular fail- Of the 103 patients studied, 32 underwent heart transplantation after 711±360 days (range, 99-1,444 days) of LVAD support and 1 patient died of infection at 4 years after transplantation. Furthermore, 25 patients remained on LVAD support at the time of writing, while 9 (9%) recovered and the LVAD was explanted. In contrast, 37 patients died during LVAD support. The major causes of death in those cases were cerebrovascular events in 18 patients, sepsis in 15, and right ventricular failure in 4.
Predictors of Survival After LVAD Implantation
With a mean follow-up period of 1,274±1,174 days (range, 34-4,102 days), the overall survival rate was 84% at 1 year, 72% at 2 years, and 59% at 3 years after LVAD implantation. Univariate analysis with a Cox proportional hazards model showed that preoperative PCPS was the only significant predictor for death after LVAD implantation (hazard ratio, 2.23, P=0.0178; 95% confidence interval, 1.15-4.31; Table 3) . Kaplan-Meier curve demonstrated that survival at 3 years Data given as mean ± SD or n (%). AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen. Other abbreviations see in Tables 1,2 . Data given as mean ± SD or n (%). Nitric oxide inhalation, nitric oxide inhalation for weaning from cardiopulmonary bypass; acute renal failure, acute renal failure requiring continuous hemofiltration; prolonged ventilation, mechanical ventilation >2-weeks; right ventricular failure, right ventricular failure requiring a right ventricular assist device or > -30-days of inotropic support after LVAD implantation; LAD, left atrial diameter; cardiac index, estimated on echocardiogram. Other abbreviations see in Tables 1,2 . PCPS and LVAD Implantation after LVAD implantation was 38% in patients with preoperative PCPS and 64% in those without, while log-rank analysis indicated significantly better survival in patients without preoperative PCPS (Figure 1) . Kaplan-Meier analysis was also used to characterize survival while on LVAD support, in which LVAD explantation or heart transplantation, and the end of the observation period were regarded as censoring events. This showed that survival during LVAD support was significantly better in patients without preoperative PCPS (Figure 2) . We also analyzed survival after heart transplantation using Kaplan-Meier curves, which demonstrated that survival after heart transplantation in patients with preoperative PCPS was as good as that of patients without preoperative PCPS (Figure 3) . Table 4 ) and early postoperative outcomes including postoperative complications, end-organ functions, and echocardiographic data obtained at 1 month after LVAD implantation (Table 5) were compared between patients with and without preoperative PCPS. Preoperatively a greater number of patients with PCPS required IABP support and mechanical ventilation. White blood cell count, and serum total bilirubin and C-reactive protein levels before LVAD implantation were significantly higher in the patients with preoperative PCPS, while hemoglobin, platelet count, and serum total protein, albumin, and sodium levels before LVAD implantation were significantly lower in those with preoperative PCPS (Table 4) . Those with preoperative PCPS required nitric oxide inhalation more frequently in order to be weaned from CPB at the time of operation, and continuous hemofiltration more frequently for postoperative acute renal failure, while a greater number of patients with preoperative PCPS required prolonged mechanical ventilation for >2 weeks after LVAD implantation. At 1 month after LVAD implantation, serum total bilirubin remained significantly higher in patients with preoperative PCPS as compared to those without, and more patients with preoperative PCPS required inotropic support to maintain an adequate LVAD pump flow. In contrast, echocardiography indicated similarly reduced LV and atrial diameters, as well as adequate cardiac output in both groups ( Table 5) .
Preoperative Variables and Early Postoperative LVAD Outcomes vs. Preoperative PCPS Preoperative variables (
Discussion
The major finding of the present study is that patients who required PCPS for preoperative cardiogenic shock had a significantly worse rate of survival during long-term LVAD support as compared to those who did not require preoperative PCPS. This result is consistent with findings presented by The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), which found that the INTERMACS Level 1 category, characterized by cardiogenic shock with life-threatening hypoperfusion, is one of the risk factors for death after LVAD implantation. 2 In the present series, mean arterial pressure was maintained at 71±16 mmHg and serum lactate level was also stabilized at 1.6±1.1 mmol/L during PCPS (normal <2.0 mmol/L). All but 1 recovered from anuria or oliguria and their urine output was maintained at 662±349 ml for the last 6 h before LVAD implantation, and serum creatine level improved from 3.4±2.0 mg/dl to 1.6±1.3 mg/dl during PCPS (P=0.0173). Although they were considered to be hemodynamically stabilized by PCPS at the time of LVAD implantation, those patients still had a significantly worse prognosis after LVAD implantation as compared with patients without preoperative PCPS. This result may emphasize the importance of timing of LVAD implantation, because it indicates that it is difficult to recover from damage caused by acute deterioration of heart failure and have an improved prognosis once acute deterioration of heart failure develops.
As compared to the INTERMACS data, the present study is unique because of the prolonged duration of LVAD support (mean, 560±391 days; range, 17-1,567 days) in the present subjects. Prolonged LVAD support has become more important not only as a bridge to transplantation but also as destination therapy. Although preoperative risk factors were analyzed in patients who underwent LVAD implantation as a destination therapy, the endpoint of the study was 90-day in-hospital mortality and the impact of preoperative factors on late mortality during long-term LVAD support remains to be elucidated. 7 The overall survival rates in the present series were 84% at 1 year and 72% at 2 years, and similarly excellent long-term LVAD support have been reported from Japan, 3,8 where the average LVAD support period before heart transplantation is >2 years. As a result, the Japanese Registry for Mechanically Assisted Circulatory Support (J-MACS registry), which was recently started, may facilitate identification of preoperative risk factors for long-term LVAD support in a future study.
Although there were no deaths within 30 days after LVAD implantation, early postoperative complications were more frequent in patients with preoperative PCPS, who required prolonged mechanical ventilation and continuous hemofiltration. At 1 month after LVAD implantation total bilirubin level was significantly higher in patients with preoperative PCPS, although the dilated LV and atrial diameters were reduced and adequate cardiac output was maintained similarly in both groups ( Table 5 ). This may indicate that patients with preoperative PCPS did not recover from preoperative end-organ dysfunction due to cardiogenic shock at 1 month after LVAD implantation, despite cardiac output being adequately maintained. Masai et al reported that a group of LVAD patients who died from multi-organ failure despite adequate hemodynamic support had increased levels of interleukin (IL)-6 and IL-8. 9 In addition, other studies have suggested that ongoing systemic inflammatory response syndrome (SIRS) plays a key role in the development of multi-organ failure in patients who die from multi-organ failure despite adequate hemodynamic support. 10 In the present series, preoperative white blood cell count and serum C-reactive protein level were significantly higher in patients with PCPS, which suggests that preoperative SIRS induced by PCPS 11 may have a harmful impact on endorgan dysfunction after LVAD implantation.
PCPS is a well-established extracorporeal life support system that can be set up quickly without a thoracotomy and provides emergency circulatory assistance for cardiogenic shock, 12 and it can be used as a bridge to a long-term mechanical circulatory support device. 4, 5 The impact of preoperative PCPS on LVAD support, however, remains inconclusive. McCarthy et al found that prior PCPS was a significant risk factor for death after LVAD implantation, 13 whereas Pagani et al reported that preoperative PCPS was not a risk factor for death after LVAD implantation. 4,5 When we compared overall survival after LVAD implantation (Figure 1 ) and survival on LVAD (Figure 2) , patients with preoperative PCPS had significantly worse survival in both analyses and the level of statistical significance was even greater for survival on LVAD (P=0.015, Figure 1 vs. P=0.0052, Figure 2 ). This suggests that the prognosis of preoperative PCPS patients was much worse while on LVAD. In contrast, survival after heart trans-TODA K et al.
plantation was good in LVAD-supported patients irrespective of pre-LVAD PCPS (Figure 3) , which shows that pre-LVAD PCPS may not lead to worse survival if the waiting time before heart transplantation, which is currently as long as 2 years in Japan because of donor shortage, could be reduced.
The incidence of right ventricular failure after LVAD implantation was higher in patients with preoperative PCPS, 5 and preoperative circulatory support was the most significant risk factor for mechanical right ventricular support after LVAD implantation. 14 In the present series, more patients with preoperative PCPS developed right ventricular failure, which required prolonged i.v. inotropic support after LVAD implantation. This increased incidence of right ventricular failure in patients with preoperative PCPS may be attributable in part to lung injury exacerbated by preoperative PCPS, 11 in addition to pre-existing right ventricular dysfunction, which is unmasked with the increase in right-sided preload afforded by LVAD support. 15 This speculation is supported by the fact that more patients with preoperative PCPS required nitric oxide inhalation for reduction of pulmonary vascular resistance in order to be weaned from CPB. Further studies are necessary to clarify to what extent preoperative PCPS itself affects right ventricular function by inducing lung injury.
We utilized right ventricular mechanical support in 2 patients who required preoperative PCPS, while such support was not required in any patients without preoperative PCPS. Kirsch et al were more aggressive in utilizing mechanical right ventricular support in patients who underwent LVAD implantation, and 79% of their patients received mechanical right ventricular support. 16 As shown in Table 5 , patients who required preoperative PCPS developed right ventricular failure more frequently (36% vs. 15%, P=0.0431) and their total bilirubin level was higher (3.4±5.8 mg/dl vs. 1.6±2.3 mg/dl, P=0.0276) at 1 month after LVAD implantation as compared with patients without preoperative PCPS. These results indicate that some patients who initially required PCPS developed right ventricular failure and hepatic failure after LVAD implantation, which may have been the reasons for the worse survival in patients with preoperative PCPS. When we compared the incidence of postoperative right ventricular dysfunction requiring inotropic support and total bilirubin level between patients who died within 100 days after LVAD implantation (100-day nonsurvivors) and those who survived for more than 100 days after LVAD implantation (100-day survivors) among patients with preoperative PCPS, the 100-day non-survivors required inotropic support for right ventricular dysfunction more frequently as compared with the 100-day survivors (80% vs. 20%, P=0.0403), while the total bilirubin level at 1 month after LVAD implantation was significantly higher in the 100-day non-survivors (11.4±9.7 mg/dl vs. 1.4±1.2 mg/dl, P=0.0031). In contrast, the average duration of PCPS before LVAD implantation was similar between 100-day survivors and non-survivors (5.6±6.2 days vs. 7.0±13.9 days, P=0.6498). We speculate that more aggressive mechanical right ventricular support for patients with worse postoperative right ventricular function may improve the prognosis of high-risk patients with preoperative PCPS.
In order to avoid postoperative right ventricular failure, we have considered a broad spectrum of preventative measures and maneuvers. Intraoperatively, we attempt to avoid cardioplegic arrest as much as possible to reduce ischemic insult to the right ventricle, and it was applied in only 9 of the present patients who required concomitant procedures. In addition, if tricuspid regurgitation is greater than mild and postoperative right ventricular failure is anticipated, we perform a tricuspid annuloplasty to increase forward flow from the right ventricle.
We also place venting cannulae in the pulmonary artery to prevent congestion of pulmonary circulation, when anastomosing an apical cuff on a beating heart. When weaning from CPB, we utilize inotropes, PDEi, and nitric oxide inhalation to maintain adequate LVAD flow. Preoperative cardiac index <2.2 L · min -1 · m -2 is reported to be the most significant predictor of mechanical right ventricular support in LVAD implantation, 17 and that index was below that level in 49% of the present patients without preoperative PCPS. The intraoperative and postoperative management protocol, however, allowed all of the patients without preoperative PCPS to maintain an adequate cardiac output without mechanical right ventricular support at 1 month after LVAD implantation ( Table 5) .
Study Limitations
The main limitations of the present study were the retrospective nature of the analysis and the relatively small number of studied patients, especially those with an implantable device. Such a small number did not allow differentiation between the relative impacts of the different devices. Although excellent reductions in complication rates have been reported in patients who received a small rotary pump, 18 only 5 patients received such new devices in the present series, because their use is still considered as experimental in Japan. These new technologies may improve the outcome of patients with preoperative PCPS, because such new devices have fewer complications and their smaller blood-contacting surface reduces activation of inflammatory response. 19 Another limitation of the present study was patient selection. We accepted patients with PCPS when their end-organ dysfunction was improving and they were considered to be possible candidates for heart transplantation. Except for total bilirubin level, end-organ functions were similar in patients with and without preoperative PCPS in the present series ( Table 4) . This patient selection protocol may have contributed to the zero number of mortalities within 30 days and the relatively low rate of mechanical right ventricular support after LVAD implantation in the present series. It should be noted, however, that preoperative PCPS had a significant impact on long-term survival after LVAD implantation even in selected patients considered to be possible candidates for heart transplantation.
Conclusion
We found that patients with preoperative PCPS had significantly worse survival despite adequate hemodynamic support after LVAD implantation. The present results indicate that LVAD should be used for patients with end-stage heart failure, before PCPS is required for hemodynamic support.
